Mylan recalls 15 lots of blood pressure drug in US

Mylan will recall at least 15 lots of medications containing valsartan in the U.S. after the drug was found to contain a cancer-causing impurity, according to Reuters. This is the latest recall of valsartan amid heightened safety concerns about the drug.

Advertisement

The company’s decision to recall the batches comes one day after European regulators banned sales of valsartan after the impurity, N-nitrosodiethylamine was discovered.

Over the last year, several other drugmakers, including Major Pharmaceuticals, Solco Healthcare and Teva Pharmaceuticals, have recalled valsartan products under heightened scrutiny from regulators.

Read the full report here.

More articles on pharmacy:
5 recent pharma layoffs
Novartis has spent $15B to reinvent itself
AstraZeneca starts search for new CEO under pressure from stakeholders

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.